Report highlights personalized medicines ensuring greater efficacy for rare diseases and previously untreatable conditions. Promising therapeutic developments for HIV, Parkinson’s disease, Crohn’s disease, alopecia, multiple myeloma and breast cancer on horizon ..read more

The new facilities will support the increased demand for Optimer technology.Baroness Susan Greenfield opened the new site and presented on the challenges in scientific discovery ..read more

Over the last decade, co-crystallization has become an attractive alternative to improve the physiochemical properties of drugs without affecting their pharmacology. As a result of the pharmaceutical benefits co-crystals exhibit, industrial interest is on the rise. Here Dr. Thomas Kendall, application specialist at crystallization and solid-state specialist Technobis Crystallization Systems, gives a perspective on the benefits of co-crystals and explains how they can be screened ..read more

Last week, Shionogi partnered with the Active Citizenship Network and members of the European Parliament (MEPs) to host an EU Parliament event calling for collaboration to drive policy change and implementation in the fight against antimicrobial resistance (AMR) within the EU and member states. Urgent action is needed to encourage and support the discovery and development of novel antibiotics as well as access models that reward innovation and appropriate use to address the growing threat of AMR ..read more

98 per cent of exhibitors sign up for Lab Innovations 2023 after a record breaking event this year ..read more

Collaboration with innovative Finnish software company to explore how to reduce the time and cost of drug discovery and development using quantum computers ..read more

The team behind the success of one the country’s largest science and innovation park has announced its plans to grow and double the number of people employed on site as it celebrates a decade of delivering jobs and investment in the South East ..read more

A discovery that may improve treatment options for patients with neurodegenerative diseases has been made by scientists at King’s College London and the University of Bath ..read more

Stockholm, Sweden, November 8, 2022 – Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target ..read more

Joint publication in Nature Chemistry between OMass Therapeutics’ scientists and co-founder Professor Dame Carol Robinson’s team at Oxford University. Data demonstrates the ability of native mass spectrometry (MS) to interrogate the pharmacology of the beta-1 adrenergic receptor (ß1AR), a G protein-coupled receptor (GPCR). Discovery of endogenous zinc ion as a positive allosteric modulator in well studied receptor exemplifies the potential of native MS to uncover novel insights that may be important for drug discovery ..read more